Averica Enters into Preferred Provider Agreement with Irix Pharmaceuticals
February 4, 2014
Averica’s Targeted IsolationTM Approach Results in Rapid Structure Elucidation of Impurities and Saves IRIX’s Clients Time and Money
MARLBOROUGH, MA, February 4, 2014 – Averica Discovery Services Inc., a contract research organization (CRO) with specialized expertise in small molecule analysis and purification, today announced an expansion of its existing relationship with IRIX Pharmaceuticals, Inc., a leading small molecule contract research and manufacturing organization (CRMO) that helps innovative health care industry clients bring new drugs to market. Averica will provide services to IRIX on a preferred provider basis. The agreement is non-exclusive.
Averica Discovery Services supplies a wide variety of chromatography and analytical services to pharmaceutical, biotechnology and other life sciences researchers. Averica works with its clients to speed lead optimization and early development timelines. The company provides highly pure assay material and it has substantial expertise in the isolation and structure elucidation of impurities – a valuable asset for optimizing chemistry for production of clinical trial drug supplies.
“IRIX’s leading position as a supplier of active pharmaceutical ingredients to biotechnology firms and others reflects our scientific excellence, commitment to quality and record of on-time production,” commented J. Guy Steenrod, CEO of IRIX Pharmaceuticals. “Leveraging Averica’s capabilities early in the API development process allows our customers to benefit from the most advanced science available. We are pleased to expand this relationship that has been valuable for both companies.”
Averica developed its Targeted Isolation™ process for rapid and accurate isolation of unknown impurities in mixtures. Conventional chromatographic approaches can require weeks of effort to accumulate enough material for isolation and elucidation. Averica’s Supercritical Fluid Chromatography (SFC) process is much more efficient and produces results in a fraction of the time.
“Our shared commitment to scientific excellence and outstanding customer service provides a strong rationale for extending our relationship with IRIX,” noted Jeffrey Kiplinger, PhD, president of Averica Discovery Services. “The reduction in timeline and costs delivered by our Targeted Isolation™ approach is a great example of how our services are helping innovative companies develop new medicines more efficiently.”
About Averica Discovery Services
Founded in 2007, Averica Discovery Services is a contract research organization with specialized expertise in small molecule analysis and purification. Averica works with drug discovery and development teams to speed lead optimization and timelines in early development. Its services include scalable compound supply, chiral resolution, pre-formulation and proprietary services such as Targeted Isolation™. Averica is located in the heart of the East Coast life sciences corridor, just west of Boston.
About IRIX Pharmaceuticals
IRIX Pharmaceuticals, Inc. is a science-driven small molecule contract research and manufacturing organization (CRMO) helping clients rapidly bring new drugs to market. U.S.-based IRIX is a fully-integrated active pharmaceutical ingredient (API) development and supply company with demonstrated scientific excellence and commitment to the success of its clients. Its services include preclinical and discovery support, process research and development, GLP toxicology, clinical supply, commercial production and manufacturing, stability studies and regulatory support. For more information, visit www.irixpharma.com.